Publications by authors named "George Doherty"

Claim this Profile
B
BCL-X-targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitors.
Andrew S Judd, Bhupinder Bawa, Wayne R Buck, Zhi-Fu Tao, Yingchun Li, George Doherty

Sci Adv· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KCL TEST: an open-source inspired asymptomatic SARS-CoV-2 surveillance programme in an academic institution.
Joana Reis de Andrade, Edward Scourfield, Shilpa Lekhraj Peswani-Sajnani, Kate Poulton, Thomas Ap Rees, George Doherty

Biol Methods Protoc· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The RNA binding proteins and are dysregulated in airway epithelium in human and a murine model of asthma.
Jennifer Rynne, Elena Ortiz-Zapater, Dustin C Bagley, Onofrio Zanin, George Doherty

Front Cell Dev Biol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-X Inhibitor.
Le Wang, George A Doherty, Andrew S Judd, Zhi-Fu Tao, T Matthew Hansen

ACS Med Chem Lett· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential occupational risks to healthcare workers from SARS-CoV-2 observed during a prospective observational study.
David W Eyre, Sheila F Lumley, Denise O'Donnell, Mark Campbell, Elizabeth Sims, George Doherty

Elife· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).
Michael L Curtin, H Robin Heyman, Richard F Clark, Bryan K Sorensen, George A Doherty

Bioorg Med Chem Lett· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
Yutong Jiang, Steven W Andrews, Kevin R Condroski, Brad Buckman, Vlad Serebryany, George A Doherty

J Med Chem· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A-1048400 is a novel, orally active, state-dependent neuronal calcium channel blocker that produces dose-dependent antinociception without altering hemodynamic function in rats.
Victoria E Scott, Timothy A Vortherms, Wende Niforatos, Andrew M Swensen, Torben Neelands, George Doherty

Biochem Pharmacol· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of diphenyl lactam derivatives as N-type calcium channel blockers.
George A Doherty, Pramila Bhatia, Timothy A Vortherms, Kennan C Marsh, Jill M Wetter

Bioorg Med Chem Lett· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 3-arylpropionic acids as potent agonists of sphingosine-1-phosphate receptor-1 (S1P1) with high selectivity against all other known S1P receptor subtypes.
Lin Yan, Pei Huo, George Doherty, Lesile Toth, Jeffrey J Hale

Bioorg Med Chem Lett· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of 3-(N-alkyl)aminopropylphosphonic acids as potent S1P receptor agonists.
Jeffrey J Hale, George Doherty, Leslie Toth, Zhen Li, Sander G Mills

Bioorg Med Chem Lett· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selecting against S1P3 enhances the acute cardiovascular tolerability of 3-(N-benzyl)aminopropylphosphonic acid S1P receptor agonists.
Jeffrey J Hale, George Doherty, Leslie Toth, Sander G Mills, Richard Hajdu

Bioorg Med Chem Lett· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-isonicotinoyl-(L)-4-aminophenylalanine derivatives as tight binding VLA-4 antagonists.
George A Doherty, Ginger X Yang, Edite Borges, Sharon Tong, Ermengilda D McCauley

Bioorg Med Chem Lett· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A small molecule very late antigen-4 antagonist can inhibit ovalbumin-induced lung inflammation.
Gloria C Koo, Kashmira Shah, Gloria J F Ding, Jianying Xiao, Richard Wnek, George Doherty

Am J Respir Crit Care Med· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-Tetrahydrofuroyl-(L)-phenylalanine derivatives as potent VLA-4 antagonists.
Ginger X Yang, Linda L Chang, Quang Truong, George A Doherty, Plato A Magriotis

Bioorg Med Chem Lett· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Substituted tetrahydrofuroyl-1-phenylalanine derivatives as potent and specific VLA-4 antagonists.
George A Doherty, Ginger X Yang, Edite Borges, Linda L Chang, Malcolm MacCoss

Bioorg Med Chem Lett· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-aryl 2,6-dimethoxybiphenylalanine analogues as VLA-4 antagonists.
George A Doherty, Theodore Kamenecka, Ermenegilda McCauley, Gail Van Riper, Richard A Mumford

Bioorg Med Chem Lett· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis